Table V.

Adjusted and weighted^a estimated fertilization rate^b (95% CI) among women undergoing IVF cycles.

	Womenc (n = 302 women, 421 cycles)	p-valued	Mene (n = 167 men, 240 cycles)	p-valued
8-iso-PGF  2α
T1 lower	0.69 (0.64, 0.73)	P < 0.01	0.73 (0.68, 0.77)	0.89
T2 middle	0.77 (0.73, 0.80)		0.73 (0.67, 0.79)
T3 upper	0.66 (0.61, 0.71)	P < 0.01	0.65 (0.57, 0.72)	0.11
F  2  -IsoP-M
T1 lower	0.68 (0.63, 0.73)	0.19	0.73 (0.67, 0.78)	0.43
T2 middle	0.72 (0.68, 0.76)		0.70 (0.63, 0.76)
T3 upper	0.71 (0.66, 0.76)	0.67	0.69 (0.62, 0.75)	0.81

^aModels were weighted to account for number of cycles with weights assigned using inverse number of cycles.

^bFertilization rate is defined as the ratio of fertilized oocytes to mature oocytes retrieved.

^cAdjusted for maternal age (continuous), maternal BMI (continuous), smoking (never vs. ever), primary infertility dx (male, female, unexplained) and race (white vs. other).

^d  P-value represents differences in adjusted mean proportion compared to the 2^nd tertile.

^eAdjusted for paternal age (continuous), BMI (continuous), smoking (never vs. ever), primary infertility dx (male, female, unexplained) and race (white vs. other).

Note: There was 1 cycle missing information on BMI (1 woman). There were 3 cycles missing information on fertilization rate (3 women).

Abbreviations: 8-isoprostane-PGF_2α (8-iso-PGF_2α); 8-isoprostane-PGF_2α metabolite (F₂-isoP-M); in-vitro fertilisation (IVF).